Torrent, Glenmark sign licensing agreement for co-marketing of Remogliflozin Etaboriate in India

11 Jul 2019

Torrent Pharmaceuticals (Torrent) and Glenmark Pharmaceuticals (Glenmark) have entered into a non-exclusive sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India. Under the terms of the agreement, Glenmark will receive license fees and royalties for the non-exclusive sub-license rights from Torrent. Glenmark will manufacture and supply Remogliflozin, while Torrent will market the drug under its own trademark 'Zucator' in India.

Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Related Torrent Pharmaceuticals Ltd. Links:

Torrent Pharma Share Price

2479.25 -4.15 (-0.17%) Mar 08, 18:37
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 614.85
Dr. Reddys Lab 4490.20
Lupin 1050.45
Piramal Enterprises 1917.10
Cadila Healthcare 446.10
View more..
Sensex vs Torrent Pharma
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback